Results 31 to 40 of about 5,788 (178)

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Gut and Liver, 2018
Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection.
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park   +10 more
doaj   +1 more source

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source

Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico

Annals of Hepatology, 2022
Introduction and Objectives: Death due to liver damage caused by hepatitis C virus (HCV), this agent represents one of the most frequent health threats in Mexico.
K López-Riojas, KA Galán-Huerta, AF Ruiz-Higareda, L Muñoz-Espinosa, P Cordero-Pérez, D Arellanos-Soto, S Lozano-Sepúlveda, AM Rivas-Estilla   +7 more
doaj   +1 more source

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients [PDF]

International Journal of Medical Arts, 2021
Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV.
Mohamed G. Mohamed, Mohamed B. Bastawy, Mostafa A. Elhawary, Mohamed R. Rashed   +3 more
doaj   +1 more source

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen

Kidney International Reports, 2017
There is paucity of data on sofosubvir (SOF)−based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India.
Sanjay Kumar Agarwal, Soumita Bagchi, Raj Kumar Yadav   +2 more
doaj   +1 more source

Efficacy of Sofosbuvir and Daclatasvir in Achieving the End Treatment Response and Sustained Viral Response in Patients infected with Hepatitis C Virus Genotype 3

Pakistan Armed Forces Medical Journal, 2022
Objective: To ascertain the efficacy of sofosbuvir combined with daclatasvir against hepatitis C genotype 3 infection. Study Design: Prospective longitudinal study.
Zabih Ullah, Sultan Zeb Khan, Hassam Lodhi, Hafizullah Khan, Rania Hidayat, Moiz Ahmed   +5 more
doaj   +1 more source

RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form

Pakistan Journal of Pharmaceutical Sciences, 2021
Daclatasvir dihydrochloride is an antiviral drug used in the treatment of Hepatitis C and for its estimation in drug product, no Pharmacopeial method is available.
Syed Suffdar Hussain Shah, Muhammad Iqbal Nasiri, Humera Sarwar, Aatka Ali, Syed Baqir S Naqvi, Sohail Anwer, Muhammad Kashif   +6 more
doaj   +1 more source

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

One Health & Risk Management, 2020
Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU, Liliana HODOROGEA, Tiberiu HOLBAN   +2 more
doaj   +1 more source

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

, 2015
OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults
Esmat G, BRUNETTO, MAURIZIA ROSSANA, Lawitz, Eric J, Esmat, Gamal, McPhee, Fiona, Zeuzem S, Weiland O, Sievert, William, Pockros, Paul J, Sievert W, Serfaty, Lawrence, Hirschfield GM, Rodriguez Torres M, Everson, Gregory T, Wind Rotolo M, Waked I, Hernandez D, Rustgi VK, Bourlière M, Shafran, Stephen D, Ghesquiere, Wayne, McPhee F, Kwo, Paul Y, Vierling JM, Ghesquiere W, Bräu, Norbert, Schnittman, Steven, Thuluvath PJ, Noviello S, Sulkowski, Mark, Fried, Michael W, Hézode C, Rodriguez-Torres, Maribel, Pol S, Bourlière, Marc, Brunetto, Maurizia R, Pockros PJ, Hirschfield, Gideon M, Serfaty L, Everson GT, Hughes EA, Hézode, Christophe, Yin PD, Bräu N, Hernandez, Dennis, Liu Z, Lawitz EJ, Noviello, Stephanie, Kwo PY, Weiland, Ola, Weis, Nina, Waked, Imam, Liu, Zhaohui, Tatum, Harvey A, Yin, Philip D, Sulkowski M, Thuluvath, Paul J, Fried MW, Tatum HA, Schnittman S., Shafran SD, Weis N, Pol, Stanislas, Rustgi, Vinod K, Hughes, Eric A, Wind-Rotolo, Megan, Vierling, John M, Zeuzem, Stefan, Rodriguez-Torres, M, Ghesquiere, W, Tatum, HA, Shafran, SD, Waked, I, Sievert, W, Hezode, C, Thuluvath, PJ, Hirschfield, GM, Esmat, G   +77 more
core   +1 more source

Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of Viral Genome to Assembly Sites.

, 2016
International audienceDaclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranous web shaping, and assembly of new virions, likely via ...
Boson, Bertrand, Chamot, Christophe, Denolly, Solène, Dreux, Marlène, Turlure, Fanny, François-Loïc, Cosset   +5 more
core   +1 more source